MEK Inhibitor Program
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About Pasithea Therapeutics
Pasithea Therapeutics is a micro-cap biotech founded in 2020 with a mission to develop innovative treatments for CNS disorders and RASopathies. Its core strategy is the targeted application of MEK inhibitors, based on the scientific rationale that dysregulation of the RAS/MAPK pathway is a key driver in conditions like NF1, ALS, and MS. The company has assembled a leadership team with deep neuroscience and drug development expertise, led by renowned neurologist and immunologist Professor Lawrence Steinman. While still in the early stages of development with a preclinical/IND-enabling pipeline, Pasithea is targeting large, underserved markets with a mechanism-driven approach.
View full company profileAbout Pasithea Therapeutics
Pasithea Therapeutics is a micro-cap biotech founded in 2020 with a mission to develop innovative treatments for CNS disorders and RASopathies. Its core strategy is the targeted application of MEK inhibitors, based on the scientific rationale that dysregulation of the RAS/MAPK pathway is a key driver in conditions like NF1, ALS, and MS. The company has assembled a leadership team with deep neuroscience and drug development expertise, led by renowned neurologist and immunologist Professor Lawrence Steinman. While still in the early stages of development with a preclinical/IND-enabling pipeline, Pasithea is targeting large, underserved markets with a mechanism-driven approach.
View full company profileAbout Pasithea Therapeutics
Pasithea Therapeutics is a micro-cap biotech founded in 2020 with a mission to develop innovative treatments for CNS disorders and RASopathies. Its core strategy is the targeted application of MEK inhibitors, based on the scientific rationale that dysregulation of the RAS/MAPK pathway is a key driver in conditions like NF1, ALS, and MS. The company has assembled a leadership team with deep neuroscience and drug development expertise, led by renowned neurologist and immunologist Professor Lawrence Steinman. While still in the early stages of development with a preclinical/IND-enabling pipeline, Pasithea is targeting large, underserved markets with a mechanism-driven approach.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT520-34 | Neuropore Therapies | Pre-clinical/Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Phase 2/3 (Platform Trial) |
| CNM-Au8 | Clene | Phase 2/3 |
| Masitinib | AB Science | Phase 3 |
| Undisclosed Program | Zhimeng Biopharma | Clinical |
| SLS-005 | Seelos Therapeutics | Platform Trial |
| PMN442 | ProMIS Neurosciences | Preclinical |
| nAV-101 | nVector | Pre-clinical |
| ALTA-808 | Alteron Therapeutics | Preclinical |
| GM6 | Genervon Biopharmaceuticals | Phase 2 |
| Lou Gehrig’s disease | Genclis | Discovery |
| Treg-directed therapy for ALS | Iltoo Pharma | Pre-clinical |